Evidence map›Paper›PMID 31730333›Full record

ArticleBioconjugate chemistry2019

Orientation-Controlled Bioconjugation of Antibodies to Silver Nanoparticles.

Nicole E Pollok, Charlie Rabin, Leilani Smith, Richard M Crooks

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioconjugate chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nicole E PollokDepartment of Chemistry , The University of Texas at Austin , 100 East 24th Street, Stop A1590 , Austin , Texas 78712-1224 , United States.
Charlie RabinDepartment of Chemistry , The University of Texas at Austin , 100 East 24th Street, Stop A1590 , Austin , Texas 78712-1224 , United States.
Leilani SmithDepartment of Chemistry , The University of Texas at Austin , 100 East 24th Street, Stop A1590 , Austin , Texas 78712-1224 , United States.
Richard M CrooksDepartment of Chemistry , The University of Texas at Austin , 100 East 24th Street, Stop A1590 , Austin , Texas 78712-1224 , United States.ORCID 0000-0001-5186-4878

Funding

A disposable NT-proBNP sensor for managing heart failure at homeR01HL137601 · NHLBI · UNIVERSITY OF TEXAS AT AUSTIN · PI CROOKS, RICHARD M · 2017 to 2020
$2.0M
NHLBI NIH HHS R01 HL137601
6 · The paper itself

Abstract

Here we report on the use of heterobifunctional cross-linkers (HBCLs) to control the number, orientation, and activity of immunoglobulin G antibodies (Abs) conjugated to silver nanoparticles (AgNPs). A hydrazone conjugation method resulted in exclusive modification of the polysaccharide chains present on the fragment crystallizable region of the Abs, leaving the antigen-binding regions accessible. Two HBCLs, each having a hydrazide terminal group, were synthesized and tested for effectiveness. The two HBCLs differed in two respects, however: (1) either a thiol or a dithiolane group was used for attachment to the AgNP; and (2) the spacer arm was either a PEG chain or an alkyl chain. Both cross-linkers immobilized 5 ± 1 Abs on the surface of each 20-nm-diameter AgNP. Electrochemical results, obtained using a half-metalloimmunoassay, proved that Abs conjugated to AgNPs via either of the two HBCLs were 4 times more active than those conjugated by the more common physisorption technique. This finding confirmed that the HBCLs exerted orientational control over the Abs. We also demonstrated that the AgNP-HBCL-Ab conjugates were stable and active for at least 2 weeks. Finally, we found that the stability of the HBCLs themselves was related to the nature of their spacer arms. Specifically, the results showed that the HBCL having the alkyl chain is chemically stable for at least 90 days, making it the preferred cross-linker for bioassays.

Indexed as

AntibodiesCross-Linking ReagentsDrug StabilityImmunoglobulin GMetal NanoparticlesSilverSulfhydryl CompoundsAntibodiesCross-Linking ReagentsImmunoglobulin GSilverSulfhydryl Compounds

Identifiers

PMID31730333
PMCPMC6920564

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.